Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03610711 · ClinicalTrials.gov registry record · Phase 1
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
A Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 3
- Study locations
NCT03610711 is a Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 21 participants, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03610711, a Phase 1 study of GastroEsophageal Cancer and Immune Checkpoint Inhibition, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Relatlimab
Study Locations (3)
Maryland
- Johns Hopkins University - Baltimore
Pennsylvania
- Alleghany Health Network - Pittsburgh
Texas
- Baylor University - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03610711
The ClinicalTrials.gov registry entry for NCT03610711 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 496-participant average among 23 other GastroEsophageal Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with GastroEsophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03610711 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT03610711 about?
NCT03610711 is a clinical study titled "REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer". This is a Phase 1B study assessing the safety of immune checkpoint inhibition after SBRT in patients with recurrent or metastatic gastroesophageal cancer (limited metastatic disease).
What is the current status of trial NCT03610711?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2019-03-06. Estimated completion is 2026-12.
What conditions does trial NCT03610711 study?
This clinical trial studies the following conditions: GastroEsophageal Cancer, Immune Checkpoint Inhibition.
What interventions are being tested in trial NCT03610711?
The interventions under investigation include: Nivolumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT03610711?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03610711 being conducted?
This trial has 3 study locations across Maryland, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for GastroEsophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
COMPLETED · Phase 1
-
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
COMPLETED · Phase 1
-
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
COMPLETED · Phase 1
-
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.